Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 12Recurrence 6Sarcoma 2Neurofibrosarcoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Wilms Tumor 1Vascular Neoplasms 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Smoldering Multiple Myeloma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Lymphoma 1Liposarcoma, Myxoid 1Liposarcoma 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1

Interventions

selinexor 1sacituzumab govitecan 1amrubicin 1Topotecan 1PM 01183 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Small Cell Lung Cancer (ES-SCLC) × selinexor × Clear all
NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
30 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡